Know Cancer

or
forgot password

A Phase II Study of MOAD (Methotrexate, Vincristine, L-asparaginase and Dexamethasone) With Subcutaneous Campath for Adults With Relapsed or Refractory Acute Leukemia (ALL)


Phase 2
18 Years
N/A
Not Enrolling
Both
Recurrent Adult Acute Lymphoblastic Leukemia

Thank you

Trial Information

A Phase II Study of MOAD (Methotrexate, Vincristine, L-asparaginase and Dexamethasone) With Subcutaneous Campath for Adults With Relapsed or Refractory Acute Leukemia (ALL)


OBJECTIVES:

I. Determine the complete response rate in patients with relapsed or refractory acute
lymphoblastic leukemia treated with methotrexate, vincristine, asparaginase, and
dexamethasone (MOAB) in combination with alemtuzumab.

II. Determine disease-free and/or overall survival of patients treated with this regimen.

III. Determine the toxic effects of this regimen in these patients. IV. Correlate the
density of CD52 molecules on the surface of leukemic lymphoblasts with response in patients
treated with this regimen.

V. Correlate the presence of minimal residual disease at the time of maximal response to
this regimen with overall outcome in these patients.

OUTLINE: This is a multicenter study.

INDUCTION THERAPY: Patients receive methotrexate IV on day 1; vincristine IV and
asparaginase intramuscularly (IM) on day 2; oral dexamethasone on days 1-10; and alemtuzumab
subcutaneously on days 1, 4, and 7. Treatment repeats every 10 days for 6 courses in the
absence of disease progression or unacceptable toxicity. Patients who achieve complete
remission (CR proceed to consolidation therapy.

CONSOLIDATION THERAPY: Patients receive methotrexate IV on day 1 and asparaginase IM on day
2. Treatment repeats every 10 days for 6 courses in the absence of disease progression or
unacceptable toxicity. Patients who remain in CR proceed to cytoreduction therapy.

CYTOREDUCTION THERAPY: Patients receive vincristine IV and methotrexate IV over 6 hours on
day 1; leucovorin calcium IV continuously over 24 hours on days 1 and 2 and then orally 4
times a day on day 3; and oral dexamethasone on days 2-6. Treatment repeats every 30 days
for 12 courses in the absence of disease progression or unacceptable toxicity. Patients who
remain in CR proceed to maintenance therapy.

MAINTENANCE THERAPY: Patients receive oral mercaptopurine on days 1-30; oral methotrexate on
days 1, 8, 15, and 22; vincristine IV on day 1; and oral dexamethasone on days 1-5.
Treatment repeats every 30 days for 36 courses in the absence of disease progression or
unacceptable toxicity.

After completion of study treatment, patients are followed periodically for 5 years from the
date of registration to this study.


Inclusion Criteria:



- Refractory or relapsed acute lymphoblastic leukemia

- Must be in first relapse or have failed to achieve complete remission with 1
prior regimen

- Prior CNS leukemia allowed provided cerebrospinal fluid is normal

- Performance status - ECOG 0-3

- Bilirubin normal

- No hepatitis B positivity

- Creatinine normal

- HIV negative

- No bacterial or fungal infection

- No infection requiring treatment with antibiotics

- No active cytomegalovirus infection by molecular detection methods

- No known hypersensitivity to alemtuzumab or its components

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No other malignancy within the past 5 years except adequately treated basal cell skin
cancer or cervical carcinoma

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Complete response rate for MOAD in combination with Campath in adult patients with relapsed or refractory ALL

Outcome Description:

With this two-stage design, the probability of stopping at the end of the first stage is 0.60 if the true response rate is 50%, but is 0.04 if the true response rate is 75%; this design has a power of 92% and a one-sided type I error of 0.09. The response at another dose level of Campath will be described in technical report separately.

Outcome Time Frame:

After 6 courses of induction treatment, assessed up to 5 years

Safety Issue:

No

Principal Investigator

Peter Wiernik

Investigator Role:

Principal Investigator

Investigator Affiliation:

Eastern Cooperative Oncology Group

Authority:

United States: Food and Drug Administration

Study ID:

NCI-2009-00518

NCT ID:

NCT00262925

Start Date:

June 2006

Completion Date:

Related Keywords:

  • Recurrent Adult Acute Lymphoblastic Leukemia
  • Leukemia
  • Leukemia, Lymphoid
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma

Name

Location

Fairview Ridges Hospital Burnsville, Minnesota  55337
Hutchinson Area Health Care Hutchinson, Minnesota  55350
United Hospital St. Paul, Minnesota  55102
Ridgeview Medical Center Waconia, Minnesota  55387
Geisinger Medical Center Danville, Pennsylvania  17822-0001
Via Christi Regional Medical Center Wichita, Kansas  67214
Wesley Medical Center Wichita, Kansas  67214
University of Wisconsin Hospital and Clinics Madison, Wisconsin  53792-0001
Montefiore Medical Center Bronx, New York  10467-2490
Lewistown Hospital Lewistown, Pennsylvania  17044
Mount Nittany Medical Center State College, Pennsylvania  16803
Cancer Center of Kansas - Chanute Chanute, Kansas  66720
Cancer Center of Kansas - Dodge City Dodge City, Kansas  67801
Cancer Center of Kansas - Newton Newton, Kansas  67114
Cancer Center of Kansas - Salina Salina, Kansas  67042
Cancer Center of Kansas - Wellington Wellington, Kansas  67152
Associates in Womens Health Wichita, Kansas  67203
Cancer Center of Kansas - Winfield Winfield, Kansas  67156
Mercy Hospital and Medical Center Chicago, Illinois  60616
Mercy Hospital Coon Rapids, Minnesota  55433
Fairview-Southdale Hospital Edina, Minnesota  55435
Abbott-Northwestern Hospital Minneapolis, Minnesota  55407
Regions Hospital Saint Paul, Minnesota  55101
Saint Francis Regional Medical Center Shakopee, Minnesota  55379
Rice Memorial Hospital Willmar, Minnesota  56201
Geisinger Medical Group State College, Pennsylvania  16801
Cancer Center of Kansas - Fort Scott Fort Scott, Kansas  66701
Cancer Center of Kansas-Independence Independence, Kansas  67301
Lawrence Memorial Hospital Lawrence, Kansas  66044
Hennepin County Medical Center Minneapolis, Minnesota  
Case Western Reserve University Cleveland, Ohio  44106
Wichita CCOP Wichita, Kansas  67214-3882
Metro-Minnesota CCOP St. Louis Park, Minnesota  
Lakeview Hospital Stillwater, Minnesota  55082
Penn State Milton S Hershey Medical Center Hershey, Pennsylvania  17033
Rush - Copley Medical Center Aurora, Illinois  60504
Joliet Oncology-Hematology Associates Limited Joliet, Illinois  60435
Edward H Kaplan MD and Associates Skokie, Illinois  60076
Carle Clinic-Urbana Main Urbana, Illinois  61801
Saint Anthony Memorial Health Center Michigan City, Indiana  46360
Mercy Medical Center-Sioux City Sioux City, Iowa  51104
Saint Luke's Regional Medical Center Sioux City, Iowa  51104
Cancer Center of Kansas - El Dorado El Dorado, Kansas  67042
Cancer Center of Kansas-Kingman Kingman, Kansas  67068
Cancer Center of Kansas - Parsons Parsons, Kansas  67357
Cancer Center of Kansas - Pratt Pratt, Kansas  67124
Cancer Center of Kansas-Wichita Medical Arts Tower Wichita, Kansas  67208
Cancer Center of Kansas - Main Office Wichita, Kansas  67214
Unity Hospital Fridley, Minnesota  55432
Saint John's Hospital - Healtheast Maplewood, Minnesota  55109
Minnesota Oncology Hematology PA-Maplewood Maplewood, Minnesota  55109
North Memorial Medical Health Center Robbinsdale, Minnesota  55422
Park Nicollet Clinic - Saint Louis Park Saint Louis Park, Minnesota  55416
Minnesota Oncology and Hematology PA-Woodbury Woodbury, Minnesota  55125
Geisinger Wyoming Valley Wilkes-Barre, Pennsylvania  18711
Cancer Center of Kansas-Liberal Liberal, Kansas  67901
Siouxland Hematology Oncology Associates Sioux City, Iowa  51101
Geisinger Medical Center-Cancer Center Hazelton Hazleton, Pennsylvania  18201